• Regenerage offers you
    a wide portfolio of regenerative treatments

    With the goal of promoting optimal health, Regenerage offers
    cutting edge regenerative medicine treatments to achieve
    regeneration, repair and rejuvenation of your entire body.

    View Treatments
  • Regenerage offers you
    a wide portfolio of regenerative treatments

    With the goal of promoting optimal health, Regenerage offers
    cutting edge regenerative medicine treatments to achieve
    regeneration, repair and rejuvenation of your entire body.

    View Treatments
  • Regenerage offers you
    a wide portfolio of regenerative treatments

    With the goal of promoting optimal health, Regenerage offers
    cutting edge regenerative medicine treatments to achieve
    regeneration, repair and rejuvenation of your entire body.

    View Treatments

Welcome

The RegenerAge System

Regenerative medicine aims to replace or regenerate damaged cells, tissues, or organs, both structurally and functionally, which have lost their optimal biological regulatory condition. Regeneration in nature can occur at the cellular, tissue, organ, structural, and even whole body levels, but in humans is naturally significantly limited with aging.

To achieve a transformational level of technological advancement in this area for humans, RegenerAge is utilizing novel combination applications of biological interventions, including stem cells, soluble regenerative biologics, proprietary nutritional bio-products, functional and regenerative based diets, bioidentical hormone replacement, and skin / aesthetic rejuvenation tools, yielding an unprecedented, integrated option for activating the natural healing processes of the body and maintaining health and wellness.

Regenerative medicine incorporates various fields of science, including genetics, biomedical engineering, tissue engineering, advanced cell technology, and evolutionary dynamics, with the goal of allowing human bodies to recover cellular function, vitality and optimizing its integrated operation.

Smart prevention is the best initial approach for any disease, but once an illness manifests as part of a person’s life, regeneration and repair are invaluable options to restore health and restructure damaged tissues and cells within the human body. Recent biotechnology related advances present wonderful opportunities for RegenerAge to improve outcomes when patients need more than traditional treatments, as well as to increase lifespan and wellness for those conscious about their health and longevity.

RegenerAge is open to working with all types of patients according to their medical status. Our treatments may help patients who suffer from a variety of chronic degenerative diseases including, but not limited to: cardiovascular conditions, diabetes, kidney damage, different types of cancer, auto-immune diseases, CNS degeneration, and hematological disorders.

Our Services

Compassionate Clinical Use

As part of its business model, RegenerAge will capitalize on expedited, experimental access for 'no option' patients around the globe. We define a 'no option' patient as any patient, with any serious medical condition, where existing standard-of-care treatment has been exhausted, who has been designated as 'end-stage' or 'terminal', who will endure needless suffering and death without further interventions, and where effective, experimental treatments may exist outside of their present sphere of care access. RegenerAge plans to take advantage of the substantial patient demand for experimental therapies, with the growing dynamics of the procedural medical travel market, integrating novel clinical development models, geographic regulatory advantages, and creative legislative initiatives to accomplish its goal, all with rigorous scientific standardization and oversight.

Procedural Medical Travel

The estimate of the current market size for procedural medical travel, defined by medical travelers who travel across international borders for the purpose of receiving medical care, is in the range of US $40-55 billion, based on approximately eleven million cross-border patients worldwide spending an average of USD 3,500-5,000 per visit, including all medically-related costs, cross-border and local transport, inpatient stay and accommodations. It is estimated that currently over a million Americans travel outside the US for medical annually. As the world population is aging and becoming more affluent at rates that surpass the availability of quality healthcare resources, out-of-pocket medical costs of critical and elective procedures will continue to rise, while nations offering universal care are faced with ever-increasing resource burdens.

“No Option” Patient - Clinical Trial Gaps

Major clinical trial gaps currently exist across all therapeutic segments that are responsible for human suffering and death. Cancer is one prime example. As a leading cause of morbidity and mortality worldwide for many decades, today there are approximately 14 million new cases diagnosed each year, with over 8 million cancer related deaths annually (patients who become 'no option'). It is estimated that less than 5% of these patients, take the initiative to participate in any available clinical studies, partially due to the substantial complexity involved with accessing current experimental programs of the industry.

COMBINATORIAL BIO-INTERVENTIONS

The overly reductionist approach that has been used to identify disease mechanisms or therapeutic targets for the last century, continues to ignore the fact disease is rarely (if ever) a simple consequence of an abnormality in a single gene product, but rather, is an emergent state involving multiple biological processes that interact in complex networks. As such, RegenerAge is championing unique, integrated, combinatorial approaches that take into account the systems based nature of most diseases, in order to affect true curative outcomes. One example of this is Bioquantine (BQ-A). BQ-A is a novel biological complex that mimics the regulatory biochemistry of living human egg (oocyte) immediately after fertilization. During this period, oocytes undertake an unprecedented set of tasks that include: restoring cellular age, reprogramming DNA to eliminate genetic and epigenetic damage, remodeling of organelles, and protection of the embryo from inflammatory, oxidative or infectious factors. All this is done in synergy to start the genetic program of embryo development, and start it on its complex pathway, step by step through organogenesis and morphogenesis. Our partner, Bioquark Inc. has found a novel way to standardize this unique biochemical complex as a therapeutic derivative, thereby generating induction of specific tissues micro-environments conducive to regeneration and cellular repair. Bioquark is the first company that has taken the step to export this natural architecture of the biochemical regulation to diseased tissues in humans.

Regenerate your health deferring payments in
3, 6 & 12 months

meses2

 

News

View All

Our Network

We thrive on scientific research and we are honored to collaborate with internationally renowned institutes, organizations & businesses.